女性非妇科盆腔及邻近肿瘤放疗后第二原发子宫癌的SEER分析
基于SEER数据库的女性直肠癌、膀胱癌及下盆腔癌患者分析显示,放疗组20年第二原发子宫癌累积发生率显著高于非放疗组,直肠癌为2.59%对0.84%,膀胱癌为1.46%对0.41%,下盆腔癌为2.30%对0.80%。多因素分析中放疗为直肠癌和膀胱癌的独立危险因素,调整后风险比分别为3.36、4.02和2.84,主要由子宫体癌驱动。发生第二原发子宫癌者中,既往放疗者总生存更差。
要点
- 放疗组20年第二原发子宫癌累积发生率显著高于非放疗组。
- 调整后HR直肠癌3.36、膀胱癌4.02、下盆腔癌2.84,以子宫体癌为主。
- 第二原发子宫癌患者中既往放疗者总生存更差。
核心结论
- 女性盆腔癌放疗与第二原发子宫癌长期风险升高相关,绝对超额风险适中。
- 子宫可能是盆腔放疗中的易感器官,支持风险适配治疗计划与长期监测。
研究设计与样本
- 基于SEER数据库的女性直肠癌、膀胱癌或下盆腔癌患者回顾性队列分析。
- 采用竞争风险回归估计第二原发子宫癌风险比,并以风险比和标准化发病比量化放疗相关超额风险。
- 按潜伏期、年龄和日历年进行动态风险比分析,并用倾向评分匹配的Kaplan-Meier法评估总生存。
主要发现
- 20年第二原发子宫癌累积发生率放疗组高于非放疗组:直肠癌2.59%对0.84%,膀胱癌1.46%对0.41%,下盆腔癌2.30%对0.80%。
- 多因素分析中放疗为直肠癌独立危险因素(HR=2.17,95%CI 1.49-3.15)和膀胱癌独立危险因素(HR=2.82,95%CI 1.06-7.48)。
- 调整后HR直肠癌3.36、膀胱癌4.02、下盆腔癌2.84,主要由子宫体癌驱动,对应SIR分别为3.04、3.19和2.69。
- 发生第二原发子宫癌的患者中,既往接受放疗者观察总生存劣于无既往放疗者。
关键数值与推荐
- 20年第二原发子宫癌累积发生率:直肠癌放疗组2.59%、非放疗组0.84%。
- 20年第二原发子宫癌累积发生率:膀胱癌放疗组1.46%、非放疗组0.41%。
- 20年第二原发子宫癌累积发生率:下盆腔癌放疗组2.30%、非放疗组0.80%。
- 多因素HR:直肠癌2.17(95%CI 1.49-3.15),膀胱癌2.82(95%CI 1.06-7.48)。
- 调整后HR:直肠癌3.36、膀胱癌4.02、下盆腔癌2.84;SIR分别为3.04、3.19、2.69。
临床怎么用
- 对女性盆腔癌放疗患者制定风险适配的治疗计划,关注子宫受照剂量。
- 放疗后长期随访中应监测第二原发子宫癌的发生。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Population-based evidence on the incidence and long-term risk of secondary uterine cancer after radiotherapy (RT) for non-gynecologic pelvic cancers remains limited. This study evaluated the incidence, temporal risk patterns, and survival outcomes of secondary uterine cancers after RT. MATERIALS AND METHODS: Female patients with rectal cancer (RC), bladder cancer (BC), or lower pelvic cancers (LPC) were identified from the Surveillance, Epidemiology, and End Results database. Competing-risk regression models were used to estimate hazard ratios for secondary uterine cancer. Hazard ratios (HR) and standardized incidence ratios (SIRs) quantified excess risk associated with RT. Dynamic HR analyses were conducted by latency, age, and calendar year. Overall survival (OS) was evaluated with Kaplan-Meier analysis with propensity score matching. RESULTS: The 20-year cumulative incidence of secondary uterine cancer was significantly higher in the RT groups than in the non-RT groups for patients with RC (2.59% vs. 0.84%), BC (1.46% vs. 0.41%), and LPC (2.30% vs. 0.80%). In multivariable analyses, RT remained an independent risk factor for the RC group (HR = 2.17, 95% CI 1.49-3.15) and BC group (HR = 2.82, 95% CI 1.06-7.48). Adjusted HRs were 3.36 for RC, 4.02 for BC, and 2.84 for LPC, predominantly driven by uterine corpus cancer, with corresponding SIRs of 3.04, 3.19, and 2.69. Among patients who developed secondary uterine cancer, those with prior RT demonstrated poorer observed OS than those without prior RT. CONCLUSION: Radiotherapy for female pelvic cancers was associated with an increased long-term risk of secondary uterine cancer regardless of irradiation direction, although the absolute excess risk was modest. These findings suggest that the uterus may be a susceptible organ during pelvic radiotherapy and support risk-adapted treatment planning and long-term surveillance.
引用
- Yuan Q, Xing X, Ma Z, et al. Radiotherapy for female non-gynecologic pelvic and adjacent cancers and secondary uterine Cancers: a SEER analysis. Radiother Oncol. 2026. PMID: 42471142. doi:10.1016/j.radonc.2026.111697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。